Finanzen von AtriCure, Inc. (ATRC)ATRCAtriCure, Inc.

AtriCure, Inc. (ATRC) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Appendage Management-United states, accounting for 34.3% of total sales, equivalent to $48.38M. Other significant revenue streams include Open Ablation - United states and Pain management. Understanding this composition is critical for investors evaluating how ATRC navigates market cycles within the Medical Equipment, Supplies & Distribution industry.

Evaluating the bottom line, AtriCure, Inc. maintains a gross margin of 77.23%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at 6.29%, while the net margin is 5.83%. These profitability ratios, combined with a Return on Equity (ROE) of 2.15%, provide a clear picture of how effectively ATRC converts its operational activities into shareholder value.

In the context of the broader market, ATRC competes directly with industry leaders such as NEOG and CDNA. With a market capitalization of $2.47B, it holds a significant position in the sector. When comparing efficiency, ATRC's gross margin of 77.23% stands against NEOG's 37.59% and CDNA's 73.50%. Such benchmarking helps identify whether AtriCure, Inc. is trading at a premium or discount relative to its financial performance.

AtriCure has shown significant improvement in its financial performance, with Q2 2026 revenue of $154 million, a 13% increase year-over-year, and a net income of $8.96 million, marking a turnaround from previous losses. The gross margin has also improved to 77.23%.